Munich, Bayern, Germany In 2012 was created TVM Capital Life Science, which is appeared as VC. The venture was found in Europe in Germany. The main department of described VC is located in the Munich.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2015. This TVM Capital Life Science works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. Considering the real fund results, this VC is 42 percentage points more often commits exit comparing to other organizations.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the TVM Capital Life Science, startups are often financed by Triathlon Medical Venture Partners, Pearl Street Venture Funds, Pappas Ventures. The meaningful sponsors for the fund in investment in the same round are Triathlon Medical Venture Partners, StandUp Ventures, Signet Healthcare Partners.
We also calculated 3 valuable employees in our database.
Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Emovi, Acer Therapeutics, CoLucid Pharmaceuticals. We can highlight the next thriving fund investment areas, such as Clinical Trials, Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Baladi Ventures | Israel, South Dakota, United States |
| Boynton Angels | Massachusetts, United States, Westborough |
| ECO Fund | China, Hangzhou, Zhejiang |
| Espace-inc | Canada, Quebec, Sherbrooke |
| EXOR N.V. | Amsterdam, Noord-Holland, The Netherlands |
| G100 Capital | - |
| ICICI Bank | India, Maharashtra, Mumbai |
| Investment Partners | Metuchen, New Jersey, United States |
| Ningbo Gaofa Automotive Control System | China, Ningbo Shi, Zhejiang |
| Oddo Meriten Asset Management | France, Ile-de-France, Paris |
| OPENAIR Equity Partners | Kansas City, Missouri, United States |
| Palm Tree Crew Investments | Florida, Miami Beach, United States |
| Shanghai Haoyi | China, Shanghai |
| SMH Venture Finance Limited | - |
| Tsinghua Holdings | Beijing, Beijing, China |
| Vayner Media | New York, New York, United States |
| Wuyi Dingfeng Touzi | China, Wuyi, Zhejiang |
| Xiamen Qingwa Hechuang Investment | China, Fujian, Xiamen |
| Xinjiang Dongfan | China, Ürümqi, Xinjiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Smart Reporting | $27M | 22 Apr 2024 | Munich, Bavaria, Germany | ||
Vektor Medical | $16M | 05 Feb 2024 | San Diego, California, United States | ||
Myo | $9M | 31 Jan 2024 | Berlin, Berlin, Germany | ||
Access Vascular | $20M | 03 Mar 2021 | Massachusetts, United States | ||
leon nanodrugs | 16 Apr 2020 | Munich, Bavaria, Germany | |||
Emovi | $11M | 04 Mar 2019 | Quebec | ||
Centogene | $29M | 13 Jun 2017 | Rostock, Mecklenburg-Vorpommern, Germany | ||
AL-S Pharma | 08 Dec 2016 | Zurich, Switzerland | |||
leon nanodrugs | $21M | 27 Jul 2015 | Bavaria |
– Access Vascular from San Francisco has closed on a Series B round of financing.
– TVM Capital Life Science led the round with a $15m commitment, with existing investors also participating.
– A company addressing the most common and costly venous access complications has closed on a Series B round of financing.
– TVM Capital Life Science led the round with a $15m commitment, with existing investors also participating.
– The company has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC® Peripherally Inserted Central Catheter and HydroMID™ Midline Catheter.
– In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.*
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Smart Reporting | $27M | 22 Apr 2024 | Munich, Bavaria, Germany | ||
Vektor Medical | $16M | 05 Feb 2024 | San Diego, California, United States | ||
Myo | $9M | 31 Jan 2024 | Berlin, Berlin, Germany | ||
Access Vascular | $20M | 03 Mar 2021 | Massachusetts, United States | ||
leon nanodrugs | 16 Apr 2020 | Munich, Bavaria, Germany | |||
Emovi | $11M | 04 Mar 2019 | Quebec | ||
Centogene | $29M | 13 Jun 2017 | Rostock, Mecklenburg-Vorpommern, Germany | ||
AL-S Pharma | 08 Dec 2016 | Zurich, Switzerland | |||
leon nanodrugs | $21M | 27 Jul 2015 | Bavaria |
